Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis

OBJECTIVE: To determine the duration of clinical benefit among patients with psoriatic arthritis (PsA) discontinuing tumour necrosis factor inhibitor (TNFi) therapy while in low disease activity (LDA), and to identify patient characteristics associated with prolonged clinical benefit. METHODS: We pe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:RMD Open
Hauptverfasser: Huynh, D H, Boyd, T A, Etzel, C J, Cox, V, Kremer, J, Mease, P, Kavanaugh, A
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMJ Publishing Group 2017
Schlagworte:
Psoriatic Arthritis
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5255890/
https://ncbi.nlm.nih.gov/pubmed/28123783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2016-000395
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge